Various Drug Therapies for AML and MDS

The chapter explores the use and efficacy of different drugs, including quizartinib and guilt rittinib, in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). They discuss the duration of response to single agent guilt rittinib and the potential benefits of combining venetoclax with guilt rittinib. Furthermore, they analyze the outcomes of a recently approved frontline flip three inhibitor, quizartinib.